Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Ductal Carcinoma In Situ: early-phase trial registry
10 of 16 indexed Breast Ductal Carcinoma In Situ trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,061 of 28,963 conditions by registered trial count.
16 US clinical trials · 10 currently recruiting · #1,061 of 28,963 conditions by registered trial count
Breast Ductal Carcinoma In Situ: 16 US clinical trials tracked, 10 recruiting.
Breast Ductal Carcinoma In Situ is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Open enrollment, early-phase tilt
Breast Ductal Carcinoma In Situ has 16 registered US clinical trials, 10 of them open to new participants right now, about 63% of the total.
- 10
- recruiting participants now
- 63%
- of trials open to enrollment
- 1
- in Phase 3-4 (later-stage)
- 5
- top sponsor: National Cancer Institute (NCI)
Corpus placement: #1,061 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Breast Ductal Carcinoma In Situ on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Ductal Carcinoma In Situ is recruiting above its size-band peers.
10 of 16 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 28,061 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Breast Ductal Carcinoma In Situ research.
National Cancer Institute (NCI) accounts for 5 of 16 trials (31.3%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Ductal Carcinoma In Situ enrolment sits around 113 participants.
Median target enrolment is 113 among the 16 trials that report a genuine target (sentinel values excluded). 8 of those (50%) plan for fewer than 100 participants.
-
Breast Ductal Carcinoma In Situ research is mostly interventional.
15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Identifying and Caring for Individuals With Inherited Cancer Syndrome
OHSU Knight Cancer Institute
NCT04494945
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
M.D. Anderson Cancer Center
NCT04169542
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
NCT06184750
A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
Roswell Park Cancer Institute
NCT06350500
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
NCT05941520
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
Thomas Jefferson University
NCT04959474
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
NCT06195306
Neoadjuvant Breast Cancer Time Restricted Eating
Thomas Jefferson University
NCT05327608
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
NCT04144023
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
NCT06538389
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
NCT01272037
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
City of Hope Medical Center
NCT05340673
Metformin and Nightly Fasting in Women With Early Breast Cancer
M.D. Anderson Cancer Center
NCT05023967
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
Northwestern University
NCT05545150
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
National Cancer Institute (NCI)
NCT03317405
EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT05086705
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Breast Ductal Carcinoma In Situ right now
10 recruiting of 16 indexed (63% open).
Phase mix: 1 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top sponsor: National Cancer Institute (NCI) (5 trials), 8 others listed. 16 shown below, recruiting first. #1,061 of 28,963 conditions by registered trial count.
Why a small condition index still matters
Thin indexes still surface the registry rows that exist for this label. Counts stay small when ClinicalTrials.gov lists few studies under the condition string, not because this page omits rows. Verify any enrollment decision on ClinicalTrials.gov and with a clinician.
Frequently Asked Questions
How many clinical trials are there for Breast Ductal Carcinoma In Situ?
PlainTrial tracks 16 US clinical trials for Breast Ductal Carcinoma In Situ, of which 10 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Breast Ductal Carcinoma In Situ?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.